gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · IQVTechnologyR&D — Physical & Biological Sciences

IQVIA Holdings Inc. (IQV)

$264.88+0.41%
Close Nov 5, 2026 · split-adjusted
Oct 30, 2026$267.33▲ 23.50% in range
Oct 30, 2025Low $156.66 · High $279.36Oct 30, 2026
What changed · written from our data
As of Nov 5, 2026

IQVIA Holdings closed at $264.88 on Nov 5, up 0.41%, 5.2% below its 52-week closing high. Volume of 1.7M shares was 1.28× its 20-day average (above normal).

Split-adjusted performance: +2.6% over one month, +48.3% over six months, +25.6% over one year.

In the quarter ended Sep 30, 2026, revenue was $4.43B, up 8.0% from a year earlier, with a net margin of 7.9%.

Short interest was 3.0M shares at the Oct 15 settlement, down 7.0% from the prior report (2.0% of float, 2.4 days to cover).

Market cap$43.65B164.8M shares
Revenue · quarter$4.43B+8.0% YoY
Diluted EPS$2.10+8.8% YoY
P/E · TTM31.3×P/S 2.5×
Net margin7.9%Gross 33.8%
Dividend yieldNone
52-week range156.66 – 279.36−5.2% from high
Volume1.7M1.28× 20-day avg
Volatility · 60d26.7%Annualised
Short % of float2.0%2.4 days to cover
Net cash-$13.64BCash $2.42B
Next earnings—Not scheduled
Split-adjusted performance
1W −3.7%1M +2.6%3M +11.0%6M +48.3%YTD +17.5%1Y +25.6%3Y +46.5%5Y +3.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum60
Revenue growth40
Net margin80
Value (low P/E)—
Size100

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →
Shares short3.0M−7.0% vs prior
Days to cover2.4Settled Oct 15
% of float2.0%
Short vol. 10d39.2%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IQVIQVIA Holdings$264.88+0.41%+48.3%+8.0%7.9%31.3$43.65B
INCYIncyte Genomics$118.01−3.94%+20.7%+14.0%−50.4%59.6$24.05BCompare
MEDPMedpace Holdings$634.98−3.32%+48.1%+8.5%19.2%34.3$17.76BCompare
CRLCharles River Laboratories International$313.02−4.07%+72.3%−2.7%−0.1%—$15.00BCompare
ABSIAbsci$9.39−10.40%+63.3%−46.4%−10443.4%—$1.61BCompare
OABIOmniAb$4.83−6.76%+228.6%+78.3%−393.9%—$704.5MCompare
NRCNRC Health$25.48−5.87%+36.0%+11.0%12.3%88.2$540.7MCompare
MXCTMaxCyte$1.31−5.76%+50.3%−14.5%−122.0%—$135.2MCompare
IBACIB Acquisition$10.81−0.46%−0.2%———$54.1MCompare

News about IQVIA Holdings

All news →
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/YZacks Investment Research · Oct 27, 2026NeutralIQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 20, 2026NeutralVEEV Expands IQVIA Partnership With Clinical Operations Software SuiteZacks Investment Research · Oct 14, 2026NeutralHere's Why IQVIA Holdings (IQV) is a Strong Momentum StockZacks Investment Research · Oct 8, 2026▲ PositiveExtensive Database & Solid Bookings Benefit IQVIA Amid Low LiquidityZacks Investment Research · Oct 2, 2026▲ Positive

Quick answers

What does IQVIA Holdings do?
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics.
What is IQV's market cap?
$43.65B, based on the Nov 5 close of $264.88.
What is IQV's P/E ratio?
31.3× trailing-twelve-month earnings of $1.39B.
Does IQVIA Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IQV is sold short?
3.0M shares, 2.0% of float, as of Oct 15, 2026.
What sector is IQV in?
Technology, in the R&D — Physical & Biological Sciences industry.

About IQVIA Holdings

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

HQ: Durham, NC95,000 employeesListed May 9, 2013iqvia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology